Browse the evidence

Ghrelin, the 'hunger hormone', directly stimulates reward pathways in the brain (VTA and NAc) to increase motivation and willingness to work for food, particularly palatable/high-fat foods.

Hunger isn't just an empty stomach; it's a biological signal that boosts your brain's reward system for food. This is why cravings feel so compelling. Understanding this biological drive can help separate the feeling of hunger from the act of eating.

GLP-1 receptor agonists directly modulate immune cell function, specifically suppressing T-cell activity and pro-inflammatory cytokine release, independent of metabolic changes.

GLP-1 medicines interact directly with your immune system. They can dampen the activity of T cells, which are key drivers of inflammation. This direct interaction helps reduce the production of inflammatory markers like TNF-α and IL-2, contributing to overall health benefits beyond blood sugar control.

GLP-1 receptor agonists reduce cardiovascular events and atherosclerosis progression through weight-loss-independent anti-inflammatory mechanisms involving endothelial and immune cell modulation.

GLP-1 medications like semaglutide and liraglutide are proven to reduce the risk of heart attacks, strokes, and cardiovascular death in people with type 2 diabetes and obesity. This protection is partly due to direct anti-inflammatory effects on blood vessels, independent of weight loss. These benefits are significant enough to be a primary reason for prescribing these drugs in high-risk patients.

Higher habitual dairy intake does NOT causally affect glycemic traits (fasting glucose, insulin, HbA1c) in adults, despite observational associations.

You do not need to avoid dairy for blood sugar control. The study suggests dairy does not causally affect glycemic traits, so it can be included in a healthy diet without fear of worsening blood sugar levels.

SPARC acts as a priming signal for the NLRP3 inflammasome in macrophages, driving chronic inflammation associated with obesity.

Chronic inflammation in obesity is driven by SPARC activating immune cells. Reducing SPARC levels, as seen with weight loss, reduces this inflammation.

GLP1R agonism reduces coronary artery disease (CAD) risk primarily through body weight lowering (BMI) rather than through the reduction of type 2 diabetes (T2D) liability.

If you are using a GLP-1 agonist (like semaglutide or tirzepatide) for heart health, the primary benefit comes from the weight loss it induces, not just from lowering blood sugar. Even if your blood sugar is already well-controlled, the drug's effect on reducing body weight is what significantly lowers your risk of coronary artery disease. This supports using these medications for cardiovascular prevention in obese individuals, regardless of diabetic status.

Stimulating the release of endogenous intestinal GIP via K-cell activation reduces food intake and body weight in mice through a central nervous system mechanism.

This research suggests that the hormone GIP, released from the gut after eating, plays a direct role in signaling satiety to the brain. While this is currently demonstrated via genetic manipulation in mice, it implies that therapies enhancing natural GIP release or mimicking its action could help reduce food intake and body weight, potentially offering an alternative or complement to GLP-1 based treatments.

In Type 1 Diabetes, fracture incidence rates have remained stable or increased in women, despite overall improvements in diabetes management and the adoption of newer technologies.

If you have Type 1 Diabetes, especially if you are a woman, be aware that your fracture risk may not be decreasing as much as it is for Type 2 Diabetes patients. Focus on preventing hypoglycemia, as low blood sugar events are linked to higher fracture risk. Discuss bone health specifically with your endocrinologist.

PPAR agonists (specifically pioglitazone) improve individual histological features of NASH (steatosis, ballooning, inflammation) and can improve fibrosis.

Pioglitazone, a PPAR agonist, improves liver inflammation and fat in NASH patients. It is taken orally (30-45 mg daily). A significant side effect is weight gain (~2.5 kg), which might be undesirable for obese patients. It can also improve fibrosis.

Targeting the melanocortin-4 receptor (MC4R) with biased agonists that favor Gq/11 signaling over Gs signaling reduces food intake and adiposity without causing adverse cardiovascular effects like hypertension and tachycardia.

If you have a specific genetic form of obesity linked to MC4R, a drug called setmelanotide may help you lose weight and improve glucose tolerance without raising your blood pressure, unlike some older treatments. This is because it targets the specific receptor pathway that controls appetite without triggering the heart-related side effects.

GLP-1RAs exhibit neuroprotective effects and may improve symptoms in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and cognitive dysfunction associated with type 2 diabetes.

For patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes, GLP-1 receptor agonists like semaglutide can significantly reduce heart failure symptoms and improve physical limitations. Additionally, there is emerging evidence that these medications may offer neuroprotective benefits, potentially slowing cognitive decline in patients with T2DM.

Adipose tissue dysfunction, specifically the release of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and free fatty acids from visceral fat, drives insulin resistance and beta-cell dysfunction in obesity.

Fat is not just stored energy; it actively sends inflammatory signals that block your body's ability to use insulin. Reducing visceral fat reduces this inflammation, thereby improving insulin sensitivity.

Premenopausal women exhibit sex-specific fat distribution characterized by preferential subcutaneous adipose tissue (SAT) storage and higher brown adipose tissue (BAT) activity, which provides metabolic protection against visceral obesity and cardiovascular disease compared to men.

If you are a premenopausal woman, your body naturally stores fat in your hips and thighs (subcutaneous) rather than around your organs (visceral), and you likely have more active brown fat for energy burning. This is a biological advantage for metabolic health. Do not equate higher total body fat with higher health risk compared to men; your distribution pattern is protective.

High baseline plasma levels of specific advanced glycation end products (G-H1) and oxidation products (2-AAA) are strongly associated with greater severity of subclinical atherosclerosis (measured by CIMT, CAC, and AAC) over a 10-year follow-up in patients with type 2 diabetes.

For people with type 2 diabetes, maintaining good blood sugar control early and consistently is crucial because high blood sugar creates lasting chemical byproducts (AGEs and OxPs) that damage blood vessels for years, even after glucose levels are normalized. This damage contributes to heart disease risk long-term, highlighting the importance of early intervention and sustained management rather than just recent control.

Bariatric surgery achieves superior long-term weight loss compared to lifestyle interventions, but this comes with complex physiological changes including transient decreases in resting metabolic rate per fat-free mass and alterations in gut peptides like GLP-1 and PYY.

Bariatric surgery is currently the most effective long-term treatment for obesity, achieving ~25% weight loss. However, it works through complex hormonal changes (like increased GLP-1) and metabolic adaptations, not just stomach size reduction. It requires lifelong medical monitoring.

Skeletal muscle transcriptomic profiling, specifically focusing on a core set of 332 insulin-sensitive genes (CORE-IS) and non-coding RNAs, provides a robust molecular signature for metabolic disease that correlates with genetic loci identified by GWAS and responds to clinical interventions.

This research does not offer a direct lifestyle or supplement intervention. Instead, it highlights that current genetic testing (GWAS) is insufficient for predicting metabolic disease risk without functional data. It suggests that future diagnostics may rely on gene expression profiles (transcriptomics) from muscle tissue to accurately assess insulin sensitivity and metabolic health, potentially guiding personalized treatment strategies for type 2 diabetes and obesity.

Cardiovascular polypills (low-dose combinations of BP, lipid, and anti-thrombotic drugs) may serve as a partial exercise mimetic for cardiovascular risk reduction, though they do not fully replicate exercise's protective mechanisms.

If you cannot exercise, a cardiovascular polypill (combining low-dose BP, lipid, and anti-clotting meds) is a viable, evidence-based strategy to reduce cardiovascular risk. It is not a perfect substitute for exercise but offers significant protection with good adherence rates.

GLP-1 receptor agonists are associated with a modestly increased risk of gallbladder and biliary disorders, particularly at higher doses and longer treatment durations.

Be aware that GLP-1 medications can slightly increase your risk of gallbladder issues, such as gallstones or inflammation. This risk is higher if you take higher doses or use the medication for a long time. While the absolute risk is low, report any severe abdominal pain to your doctor promptly.

Obesity alters the pharmacokinetics of drugs, affecting absorption, distribution, metabolism, and excretion, which may necessitate dose adjustments for certain medications.

If you have obesity, tell your doctor about all medications you take. Your body may process drugs differently, requiring dose adjustments for safety and effectiveness, especially for drugs metabolized by the liver or kidneys.

Obesity induces chronic low-grade inflammation (LGCI) via adipose tissue hypertrophy, immune cell infiltration (M1 macrophages), and cytokine release (TNF-α, IL-6, IL-1β), which disrupts insulin signaling through JNK and NF-κB pathways, leading to systemic insulin resistance and metabolic dysfunction.

If you have obesity, your body is likely in a state of chronic, low-grade inflammation that actively works against your metabolic health. This isn't just 'being fat'; it's a biological state that disrupts how your body handles insulin and energy. Addressing this inflammation through lifestyle changes (diet, exercise) or medical interventions is crucial for breaking the cycle of metabolic dysfunction.

Tirzepatide slows the rate of eGFR decline in patients with type 2 diabetes, including those with preserved kidney function (eGFR >60 mL/min/1.73 m2) and normoalbuminuria.

Even if your kidney function tests are currently normal, tirzepatide can help protect your kidneys from future decline. Clinical data shows that this medication slows the rate of kidney function loss compared to insulin, regardless of whether you currently have signs of kidney disease. This makes it a valuable preventive tool for long-term kidney health in people with type 2 diabetes.

Oral branched-chain amino acid (BCAA) supplementation provides negligible benefits for athletic performance and body composition in trained athletes, regardless of supplementation duration or dosage.

If you are an athlete, stop spending money on BCAA supplements for performance or muscle gain. The evidence shows they provide negligible benefits over a normal diet. Ensure you are eating enough total protein daily instead. BCAAs might help slightly with muscle soreness after heavy resistance training, but this is not a guaranteed or significant benefit for most people.

Roux-en-Y gastric bypass (RYGB) surgery restores gut hormone balance by elevating postprandial GLP-1 and PYY levels, which contributes to sustained weight loss and improved glucose homeostasis.

For patients who have undergone Roux-en-Y gastric bypass, the surgery works largely by changing how gut hormones signal fullness (GLP-1 and PYY). This hormonal shift helps maintain weight loss and improves blood sugar control long-term. If surgery is not an option, new combination drug therapies aim to replicate this hormonal effect.

Higher long-term circulating levels of de novo lipogenesis-related fatty acids (palmitic acid 16:0, palmitoleic acid 16:1n-7, and oleic acid 18:1n-9) are associated with increased all-cause, cardiovascular, and non-cardiovascular mortality in older adults, whereas higher levels of stearic acid (18:0) are associated with lower mortality risk.

For older adults, high levels of certain fatty acids in the blood (palmitic, palmitoleic, and oleic acids) signal higher long-term mortality risk, while stearic acid signals lower risk. These levels reflect metabolic processes like de novo lipogenesis, often driven by excess carbohydrate and alcohol intake. Focus on metabolic health markers rather than just total fat intake.